banner
You are here:HomeFor CliniciansImproving Outcomes
For Patients
What is PT/INR Self Testing?
How Self Testing Works
Benefits of Self Testing
Is Self Testing for You?
INR Meters
What People Say
Medications & Diet
Frequently Asked Questions
Get Started Now
For Clinicians
Improving Outcomes
How Self Testing Works
Which Patients Qualify
What Doctors Say
About the Meters
Frequently Asked Questions
Prescription - Rx
Clinician Info Kit
Published Research
Practical Implementation

About Us

A New Standard of Care for Improving Patient Outcomes

PT/INR patient self-testing is approved by Medicare (CMS) and most private insurers for these conditions requiring warfarin oral anticoagulation:

  • chronic atrial fibrillation

  • mechanical heart valves

  • deep vein thrombosis

  • pulmonary embolism 

  • hypercoagulable state

     

Clinical benefits of self-testing:

  • Helps maintain patients in therapeutic range, which may reduce the potential for drug-related complications and emergency room visits

  • Reducing the potential for drug-related complications and ER visits may have a positive impact on costs associated with anti-coagulation

  • Provides timely alert to clinicians when patients are out of range

     

Provides greater support for anticoagulation therapy compliance:

  • Recent study in the New England Journal of Medicine cites warfarin as the leading cause of emergency room admissions among the elderly.

  • By contacting patients with reminders to test if weekly results are not received, Remote Cardiac Services' Patient Self-Testing service offers clinicians and their patients a high degree of support for anticoagulation therapy.

 

When testing patients with mechanical heart valves, Medicare advises: “In order to achieve time in therapeutic range of greater than 90%, a patient most likely needs to test once a week.” 1

 

Learn about recently published research on patient self-testing

 

 

 


1 Decision Memo for Prothrombin Time (INR) Monitor for Home Anticoagulation Management. (#CAG-00087N) National Coverage Analysis. Baltimore, MD: Centers for Medicare and Medicaid Services; September 18, 2001

     Helps maintain patients in therapeutic range, which may reduce the potential for drug-related complications and emergency room visits